Moreover, KRYSTAL-7 is a phase 2 study designed to further evaluate the clinical activity of adagrasib in combination with pembrolizumab administered as first-line treatment for patients with advanced NSCLC harboring a KRAS G12C mutation [56]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.